Real World Experience of Letermovir (LTV) Prophylaxis (Px) for the Prevention of Cytomegalovirus Infection (CMVi) in the Adult CMV Seropositive Recipients (R+) of Allogeneic Hematopoietic Cell Transplantation (HCT) Patients (pts).
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.590
Abstract: CMVi leads to significant morbidity in R+ HCT and preemptive therapy (PET) has been the standard of care. LTV was FDA-approved in Nov. 2017 for CMVi prevention in R+ HCT. Besides the clinical trials, there… read more here.
Keywords: risk; ltv; hct; cmvi ... See more keywords
Clinical burden of late-onset, clinically significant CMV infection beyond 100 days in allo-HSCT patients after letermovir prophylaxis
Sign Up to like & getrecommendations! Published in 2025 at "Current Medical Research and Opinion"
DOI: 10.1080/03007995.2025.2470733
Abstract: Abstract Objective Letermovir (LET) is effective for preventing cytomegalovirus infection (CMVi) and CMV disease in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, clinically significant (cs)-CMVi can occur after LET cessation. We retrospectively evaluated… read more here.
Keywords: cmvi; allo hsct; late onset; burden late ... See more keywords
Update on prevention of cytomegalovirus in hematopoietic cell transplantation
Sign Up to like & getrecommendations! Published in 2019 at "Current Opinion in Infectious Diseases"
DOI: 10.1097/qco.0000000000000517
Abstract: Purpose of review Cytomegalovirus infection (CMVi) has been the troll of allogeneic hematopoietic cell transplantation (allo-HCT). Over the last 4 decades various approaches have been adopted to minimize the burden from CMVi. There has been… read more here.
Keywords: prevention; hematopoietic cell; cmv; cell transplantation ... See more keywords